Bilateral hypoglossal nerve stimulation for treatment of adult obstructive sleep apnoea

Peter R. Eastwood, Maree Barnes, Stuart G. MacKay, John R. Wheatley, David R. Hillman, Xuân Lan Nguyên, Richard Lewis, Matthew C. Campbell, Boris Pételle, Jennifer H. Walsh, Andrew C. Jones, Carsten E. Palme, Alain Bizon, Nicole Meslier, Chloé Bertolus, Kathleen J. Maddison, Laurent Laccourreye, Guillaume Raux, Katleen Denoncin, Valérie AttaliFrédéric Gagnadoux, Sandrine H. Launois

Research output: Contribution to journalArticlepeer-review

80 Citations (Scopus)
11 Downloads (Pure)


Background and aim: Hypoglossal nerve stimulation (HNS) decreases obstructive sleep apnoea (OSA) severity via genioglossus muscle activation and decreased upper airway collapsibility. This study assessed the safety and effectiveness at 6 months post-implantation of a novel device delivering bilateral HNS via a small implanted electrode activated by a unit worn externally, to treat OSA: the Genio™ system. Methods: This prospective, open-label, non-randomised, single-arm treatment study was conducted at eight centres in three countries (Australia, France and the UK). Primary outcomes were incidence of device-related serious adverse events and change in the apnoea-hypopnoea index (AHI). The secondary outcome was the change in the 4% oxygen desaturation index (ODI). Additional outcomes included measures of sleepiness, quality of life, snoring and device use. This trial was registered with, number NCT03048604. Results: 22 out of 27 implanted participants (63% male, aged 55.9±12.0 years, body mass index (BMI) 27.4 ±3.0 kg·m−2) completed the protocol. At 6 months BMI was unchanged (p=0.85); AHI decreased from 23.7 ±12.2 to 12.9±10.1 events·h−1, a mean change of 10.8 events·h−1 (p<0.001); and ODI decreased from 19.1±11.2 to 9.8±6.9 events·h−1, a mean change of 9.3 events·h−1 (p<0.001). Daytime sleepiness (Epworth Sleepiness Scale; p=0.01) and sleep-related quality of life (Functional Outcomes of Sleep Questionnaire-10; p=0.02) both improved significantly. The number of bed partners reporting loud, very intense snoring, or leaving the bedroom due to participant snoring decreased from 96% to 35%. 91% of participants reported device use >5 days per week, and 77% reported use for >5 h per night. No device-related serious adverse events occurred during the 6-month post-implantation period. Conclusions: Bilateral HNS using the Genio™ system reduces OSA severity and improves quality of life without device-related complications. The results are comparable with previously published HNS systems despite minimal implanted components and a simple stimulation algorithm.

Original languageEnglish
Article number1901320
Number of pages11
JournalEuropean Respiratory Journal
Issue number1
Publication statusPublished - 1 Jan 2020
Externally publishedYes


  • Hypoglossal nerve stimulation (HNS)
  • obstructive sleep apnoea (OSA)
  • Clinical trial


Dive into the research topics of 'Bilateral hypoglossal nerve stimulation for treatment of adult obstructive sleep apnoea'. Together they form a unique fingerprint.

Cite this